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addition, to meet clinical expectations of practicing specialists, 
new technology must stay consistent with fundamental medical 
and surgical principles.
Transcatheter aortic valve implantation (TAVI) is considered a 
feasible technique, which may be used as an alternative to 
standard surgical aortic valve replacement in selective cases. 
The procedure is performed on the beating heart without the 
need for a sternotomy or cardio-pulmonary bypass. Currently, 
2 devices are CE marked and one is approved by the FDA 
without restriction. The procedure may be performed via the 
transfemoral, subclavian and transapical approaches or via a 
mini sternotomy.
SA Heart and the respective boards of SASCI and SCTSSA, via 
this combined and most up-to-date consensus agreement, 
hereby adopt in line with the principles of evidence-based 
medicine, the TAVI procedure for aortic stenosis after con-
sidering the most recent published evidence and the various 
multinational society position statements and guidelines 
concerning TAVI.
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BACKGROUND  
The South African Heart Association (SA Heart) together with 
its major special interest groups, SASCI and SCTSSA represent 
the scientific, educational, socio-economic, ethical and 
professional interest of cardiac specialists, with a combined 
membership of over 200 members: We are the only national 
organisations exclusively representing practicing cardiologists 
and cardiothoracic surgeons. We are dedicated to maintain the 
highest standards of practice for our specialists and the highest 
quality of care for  patients who require our care. As a result, 
we seek to serve as a knowledge resource for patients and 
funders in matters related to new technology used in our 
disciplines.
The introduction of new technology is a constant in modern 
medicine. While authorities in the U.S.A. and European Union, 
such as the Food and Drug Administration (FDA) and 
Conformité Européenne (CE) respectively provide regulatory 
clearance on safety and effectiveness, practicing medical 
practitioners may require scientific evidence on net health 
outcomes before offering new procedures to their patients. In 
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LITERATURE REVIEW
This consensus guideline considers the literature reviewed, for 
the second time since June 2008, as at April 2011, by the 
National Institute for Health Clinical Excellence (NICE)(1) as 
significant new evidence has been published and much 
experience gained. 
The European Society of Cardiology (ESC)(2) and the European 
Association of Cardiothoracic Surgeons (EACTS)(3) Guidelines 
as issued by respective bodies were also reviewed. The 
published PARTNER(4,5) cohort A and B which represent 
randomised data confirming clinical effectiveness of TAVI were 
also considered.  
CONSENSUS GUIDELINES ON 
TRANSCATHETER AORTIC VALVE 
IMPLANTATION (TAVI)
Members of the SA Heart Association, SASCI and SCTSSA 
(special interest groups of the SA Heart Association) with 
experience in the technique and knowledge of the TAVI 
literature have agreed the following consensus statement:
Requirements and structure of the multidisciplinary 
team (MDT)
 ■ The performance of TAVI, ab initio, should be restricted to 
a limited number of high-volume centres, which have both 
cardiology and cardiac surgery departments, with expertise 
in structural heart disease intervention and high risk valvular 
surgery. Interventional cardiologists should be experienced 
in catheter-based valvular interventions and peripheral 
access using large devices. Cardiac surgeons should be 
experienced in valve surgery and the management of 
complex cases.
 ■ TAVI should currently be reserved for patients who have 
been considered by a multidisciplinary team (MDT) (2 
surgeons, 2 interventional cardiologists, 1 cardiac anaesthe-
tist and cardiac imaging specialists) who consider the risk/
benefit ratio of open heart surgery and TAVI to favour 
TAVI. 
 ■ Patients should be screened into a TAVI programme by this 
MDT team and not by any individual speciality.
 ■ Formal training of the implanting team should include:
 ■ Didactic theoretical training;
 ■ Simulator training where available;
 ■ A visit to an experienced centre to observe TAVI cases; 
and
 ■  Support for the initial cases at any site by a proctor until 
the proctor has certified the centre to be independent.
Patient entry criteria/selection
 ■ Mandatory pre-requisites for catheter-guided aortic valve 
replacement: 
 ■ Proof of symptomatic, degenerative, severe aortic valve 
stenosis; 
 ■ Evaluation of risk scores; and
 ■ Review of the possibilities of catheter-guided aortic 
valve replacement based on the valvular annular size by 
means of echocardiography. 
 ■ TAVI can be considered for patients in whom surgical heart 
valve procedures can only be performed with a high risk - if 
at all – for example: 
 ■ Patients with severe malformation of the thorax or a 
porcelain aorta; 
 ■ Previously operated patients with significant co-
morbidity or patients with severe adhesion in the 
thorax due to radiation;  
 ■ Older patients in whom a high surgical risk can be 
anticipated based on the STS or EuroSCORE; and
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 ■ Old or very old patients with a degenerated bio-
prostheses.
 ■ TAVI should be performed only in calcific aortic stenosis.
 ■ TAVI should only be proposed in patients with symptoms 
that can definitely be attributed to valve disease.
 ■ TAVI should currently be restricted to patients at high risk 
or with contra-indications for surgery. It is premature to 
consider using it in patients who are good surgical 
candidates. The EuroSCORE and STS score are not accu-
rate predictors of mortality, since these scores are not 
validated for the high risk population. Recent peer-reviewed 
publications have demonstrated that logistic Euroscore is a 
severe overestimation of operative risk in the targeted 
patient population. Nevertheless since no more accurate 
scoring systems are available, and in the light of the position 
statement of the EACTS and ESC, a joint decision should 
be taken by a team of cardiac surgeons and cardiologists 
with a vast experience in heart valve surgery and 
percutaneous interventions for structural heart disease.
 ■ Patients with a contra-indication for surgery and/or at least 
a logistic EuroSCORE >20% or STS score >10% might be 
eligible for the procedure.
 ■ TAVI is seldom considered in patients <70 years of age. 
However, age alone is not sufficient for its use instead of 
surgery. TAVI should not be performed in patients whose 
life expectancy is <1 year, who should be managed 
conservatively.
 ■ Preference of the patient is not sufficient to choose for a 
transcatheter heart valve procedure over conventional 
surgery, unless the patient has independently consulted 
with both a cardiological and a surgical member of the 
team.
 ■ Other forms of aortic valve disease such as a failing aortic 
bioprostheses may be treated, where deemed appropriate.
Contra-indications
 ■ Significant other valve lesions or coronary artery disease 
that requires coronary bypass surgery. 
 ■ Patients whose life expectancy is expected to be <1 year.
Establishing a TAVI programme
 ■ The centre should be sufficiently equipped to perform 
transcatheter procedures safely.(2,3)
 ■ Minimum infrastructure requirements include: 
 ■ The ability to set up a MDT (as above);
 ■ Immediate availability of trans-thoracic and trans-oeso-
phageal echocardiography;
 ■ Availability of a dedicated cardiac catheterization 
laboratory or hybrid theatre. (A theatre with “C” arm 
screening facilities is generally not appropriate for TAVI 
procedures.);
 ■ CT scanning facilities;
 ■ Immediate availability of perfusion services in case of 
the need for emergency femora-femoral bypass;
 ■ On-site availability of a surgical recovery area and 
intensive care with staff experienced in the aftercare of 
patients who had surgical aortic valve replacement;
 ■ Facilities for immediate renal support if necessary; and
 ■ Immediate access to vascular surgery and interventional 
radiology to deal with peripheral vascular complications.
 ■ The above requirements will mean that this procedure 
should only be performed in a unit currently carrying out 
surgical aortic valve replacement.
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